TDMS Study 61427-07 Pathology Tables
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 FINAL#2/RATS Facility: Battelle Northwest Chemical CAS #: 1314-62-1 Lock Date: 08/18/99 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 14 20 17 15 Natural Death 3 6 4 5 Survivors Terminal Sacrifice 33 24 29 30 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Colon (48) (47) (48) (49) Intestine Small, Duodenum (48) (47) (48) (49) Histiocytic Sarcoma 1 (2%) Liver (50) (50) (50) (50) Hepatocellular Adenoma 1 (2%) Mesentery (9) (20) (22) (15) Histiocytic Sarcoma 1 (5%) Oral Mucosa (1) (1) Pharyngeal, Squamous Cell Carcinoma 1 (100%) Pharyngeal, Squamous Cell Papilloma 1 (100%) Pancreas (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) Salivary Glands (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Stomach, Forestomach (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Stomach, Glandular (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Tongue (2) (4) (2) Squamous Cell Carcinoma 1 (50%) Squamous Cell Papilloma 1 (50%) 1 (25%) Tooth (3) (2) (2) (1) Odontoma 1 (50%) ____________________________________________________________________________________________________________________________________ Page 2 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Carcinoma, Metastatic, Mammary Gland 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (49) (50) (50) (50) Adrenal Medulla (49) (50) (50) (50) Pheochromocytoma Malignant 1 (2%) 1 (2%) Pheochromocytoma Benign 2 (4%) 2 (4%) 1 (2%) 1 (2%) Islets, Pancreatic (49) (50) (49) (50) Adenoma 1 (2%) 1 (2%) 1 (2%) Carcinoma 1 (2%) Pituitary Gland (49) (50) (49) (50) Pars Distalis, Adenoma 31 (63%) 29 (58%) 24 (49%) 30 (60%) Thyroid Gland (50) (50) (50) (50) Bilateral, C-Cell, Adenoma 1 (2%) C-Cell, Adenoma 2 (4%) 4 (8%) 3 (6%) 3 (6%) C-Cell, Carcinoma 1 (2%) 1 (2%) Follicular Cell, Carcinoma 2 (4%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (50) (50) (49) (50) Adenoma 2 (4%) 3 (6%) Carcinoma 1 (2%) 2 (4%) 3 (6%) Histiocytic Sarcoma 1 (2%) Ovary (50) (50) (50) (50) Carcinoma 1 (2%) Granulosa Cell Tumor Benign 1 (2%) 1 (2%) Uterus (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) Polyp Stromal 6 (12%) 3 (6%) 7 (14%) 13 (26%) Sarcoma Stromal 1 (2%) ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) (50) Lymph Node (3) (3) (3) (2) Carcinoma, Metastatic, Mammary Gland 1 (33%) Pancreatic, Histiocytic Sarcoma 1 (33%) Lymph Node, Bronchial (42) (45) (44) (44) Histiocytic Sarcoma 1 (2%) Lymph Node, Mandibular (42) (41) (45) (46) Lymph Node, Mesenteric (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Lymph Node, Mediastinal (48) (50) (50) (48) Carcinoma, Metastatic, Thyroid Gland 1 (2%) Histiocytic Sarcoma 1 (2%) Spleen (50) (50) (50) (50) Thymus (49) (50) (50) (50) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (50) (50) (50) Adenoma 1 (2%) Carcinoma 1 (2%) 2 (4%) 2 (4%) 3 (6%) Carcinoma, Multiple 1 (2%) Fibroadenoma 12 (24%) 9 (18%) 18 (36%) 18 (36%) Fibroadenoma, Multiple 4 (8%) 4 (8%) 2 (4%) 3 (6%) Skin (50) (50) (50) (50) Fibrosarcoma 1 (2%) Keratoacanthoma, Multiple 1 (2%) Schwannoma Malignant 1 (2%) Pinna, Neural Crest Tumor, Benign 1 (2%) 1 (2%) Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%) 1 (2%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (2) (2) (2) Rhabdomyosarcoma 1 (50%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) Astrocytoma Malignant 2 (4%) 2 (4%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Larynx (50) (49) (49) (50) Histiocytic Sarcoma 1 (2%) Lung (49) (49) (50) (50) Alveolar/Bronchiolar Adenoma 3 (6%) 1 (2%) Alveolar/Bronchiolar Carcinoma 1 (2%) Carcinoma, Metastatic, Clitoral Gland 1 (2%) Fibrosarcoma, Metastatic, Skin 1 (2%) Mediastinum, Histiocytic Sarcoma 1 (2%) Nose (50) (50) (50) (50) Chondroma 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) Urinary Bladder (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Papilloma 1 (2%) Sarcoma Stromal, Metastatic, Uterus 1 (2%) Transitional Epithelium, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 1 (2%) 1 (2%) Leukemia Mononuclear 21 (42%) 23 (46%) 22 (44%) 15 (30%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 5 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 47 47 46 45 Total Primary Neoplasms 93 93 96 96 Total Animals with Benign Neoplasms 41 39 41 39 Total Benign Neoplasms 64 59 64 71 Total Animals with Malignant Neoplasms 28 29 27 22 Total Malignant Neoplasms 29 34 32 25 Total Animals with Metastatic Neoplasms 2 1 2 Total Metastatic Neoplasm 3 1 2 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 6 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 25 17 18 13 Natural Death 5 4 6 10 Survivors Terminal Sacrifice 20 29 26 27 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (50) (50) (49) (50) Intestine Large, Cecum (46) (48) (45) (46) Polyp Adenomatous 1 (2%) Intestine Small, Jejunum (45) (47) (45) (43) Carcinoma 1 (2%) Liver (50) (50) (49) (50) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Hepatocellular Carcinoma 1 (2%) Hepatocellular Adenoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Mesentery (8) (18) (12) (9) Fibrous Histiocytoma, Metastatic, Skin 1 (13%) Oral Mucosa (3) (4) Squamous Cell Carcinoma 1 (25%) Squamous Cell Papilloma 1 (33%) Pharyngeal, Squamous Cell Papilloma 1 (33%) Pancreas (50) (50) (49) (50) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Salivary Glands (49) (50) (49) (50) Tongue (1) (2) Squamous Cell Papilloma 1 (50%) Tooth (7) (1) (2) (5) Odontoma 1 (20%) ____________________________________________________________________________________________________________________________________ Page 7 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (49) (50) Carcinoma, Metastatic, Mammary Gland 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Pericardium, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (49) (50) Sarcoma, Metastatic, Skin 1 (2%) Adrenal Medulla (50) (50) (49) (50) Ganglioneuroma 1 (2%) Pheochromocytoma Malignant 1 (2%) 2 (4%) Pheochromocytoma Complex 2 (4%) Pheochromocytoma Benign 4 (8%) 10 (20%) 6 (12%) 6 (12%) Bilateral, Pheochromocytoma Benign 1 (2%) Islets, Pancreatic (50) (50) (49) (50) Adenoma 1 (2%) 3 (6%) 1 (2%) 2 (4%) Carcinoma 1 (2%) 4 (8%) 3 (6%) Parathyroid Gland (49) (49) (48) (48) Carcinoma, Metastatic, Thyroid Gland 1 (2%) Pituitary Gland (50) (50) (50) (50) Pars Distalis, Adenoma 35 (70%) 35 (70%) 39 (78%) 32 (64%) Pars Intermedia, Adenoma 1 (2%) Thyroid Gland (50) (50) (49) (50) Sarcoma, Metastatic, Skin 1 (2%) C-Cell, Adenoma 1 (2%) 4 (8%) 4 (8%) 2 (4%) C-Cell, Carcinoma 1 (2%) 1 (2%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (2) ____________________________________________________________________________________________________________________________________ Page 8 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (50) (49) (50) Preputial Gland (50) (50) (49) (50) Carcinoma 2 (4%) 2 (4%) 2 (4%) Testes (50) (50) (50) (50) Bilateral, Interstitial Cell, Adenoma 21 (42%) 21 (42%) 18 (36%) 23 (46%) Interstitial Cell, Adenoma 15 (30%) 11 (22%) 16 (32%) 11 (22%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) (50) Sarcoma, Metastatic, Skin 1 (2%) Lymph Node (2) (3) (2) (5) Lymph Node, Bronchial (39) (44) (47) (44) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Fibrous Histiocytoma, Metastatic, Skin 1 (3%) Sarcoma, Metastatic, Skin 1 (3%) Lymph Node, Mandibular (44) (48) (46) (45) Sarcoma, Metastatic, Skin 1 (2%) Lymph Node, Mesenteric (50) (50) (49) (50) Lymph Node, Mediastinal (45) (47) (46) (44) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Spleen (50) (50) (48) (50) Thymus (49) (49) (49) (50) Thymoma Benign 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (48) (50) (49) (50) Carcinoma, Multiple 1 (2%) Fibroadenoma 2 (4%) 2 (4%) 1 (2%) Skin (50) (50) (50) (50) Basal Cell Adenoma 1 (2%) 1 (2%) Basal Cell Adenoma, Multiple 1 (2%) Basal Cell Carcinoma 1 (2%) 1 (2%) Fibrosarcoma 1 (2%) Fibrous Histiocytoma 1 (2%) Page 9 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM - cont Keratoacanthoma 3 (6%) 6 (12%) 2 (4%) 2 (4%) Keratoacanthoma, Multiple 1 (2%) Neural Crest Tumor, Benign 1 (2%) Schwannoma Benign 1 (2%) Squamous Cell Papilloma 1 (2%) 1 (2%) Trichoepithelioma 1 (2%) Subcutaneous Tissue, Fibroma 2 (4%) 4 (8%) 2 (4%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%) Subcutaneous Tissue, Lipoma 2 (4%) 3 (6%) 1 (2%) Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Fibrosarcoma, Metastatic, Skin 1 (2%) Cranium, Sarcoma, Metastatic, Skin 1 (2%) Femur, Osteosarcoma 1 (2%) Mandible, Osteosarcoma 1 (2%) Skeletal Muscle (2) (2) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (50%) Carcinoma, Metastatic, Mammary Gland 1 (50%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (49) (50) Glioma Malignant 1 (2%) Meningioma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Larynx (49) (50) (50) (49) Lung (50) (49) (48) (50) Alveolar/Bronchiolar Adenoma 4 (8%) 6 (12%) 5 (10%) 6 (12%) Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 3 (6%) Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Page 10 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Carcinoma, Metastatic, Mammary Gland 1 (2%) Fibrous Histiocytoma, Metastatic, Skin 2 (4%) Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%) Pheochromocytoma Malignant, Metastatic, Adrenal Medulla 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Squamous Cell Carcinoma, Metastatic, Oral Mucosa 1 (2%) Pleura (2) (1) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (50%) Trachea (50) (50) (49) (50) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Lacrimal Gland (1) Fibrosarcoma, Metastatic, Skin 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (49) (50) Renal Tubule, Adenoma 1 (2%) Renal Tubule, Carcinoma 1 (2%) Urinary Bladder (49) (50) (48) (50) Papilloma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Leukemia Mononuclear 22 (44%) 21 (42%) 19 (38%) 17 (34%) Lymphoma Malignant 1 (2%) Mesothelioma Malignant 1 (2%) 3 (6%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 11 NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 50 50 49 49 Total Primary Neoplasms 124 147 138 120 Total Animals with Benign Neoplasms 48 47 49 46 Total Benign Neoplasms 93 108 103 93 Total Animals with Malignant Neoplasms 28 31 30 24 Total Malignant Neoplasms 31 39 35 27 Total Animals with Metastatic Neoplasms 5 4 2 1 Total Metastatic Neoplasm 19 6 7 1 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 12 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------